Overall survival and progression-free survival in patients with advanced ovarian cancer in the bevacizumab era : experience in an oncology center in Medellín-Colombia. Supervivencia global y supervivencia libre de progresión en pacientes con cáncer de ovario avanzado en la era del bevacizumab : experiencia en un centro oncológico de Medellín-Colombia.

Abstract

Objective: Describe the clinical characteristics, progression-free survival (PFS), and overall survival (OS) in a cohort of patients with advanced ovarian cancer and establish the differences between those treated with chemotherapy with or without bevacizumab at Clínica de Oncología Astorga, Medellín. Material and methods: We carried out an observational study of a retrospective cohort of patients who received treatment between 2012 and 2018. OS and PFS of the treatment subgroups were compared using Kaplan-Meier curves and the log-rank test; also, the hazard ratio (HR) was estimated. Results: We evaluated 49 patients. The median age was 63 years (IQR: 54-68). Among the patients evaluated 29 (59%) had serous carcinoma, 24 (49%) in stage IV, 35 (71%) required surgery, primary cytoreductive surgery was performed in 23/35 patients (66%), and 24 (49%) patients received bevacizumab. Median follow-up was 24 months, 32 patients developed disease progression, and 22 patients died. Median OS was 46 (95% CI 16-75), 37 (95% CI 21-53), and 61 (95% CI 15-106) months in the total cohort, with and without bevacizumab, respectively. Median PFS was 20 (95% CI 16–24), 18 (95% CI 13-23), and 36 (95% CI 13-59) months in the total cohort, with and without bevacizumab, respectively. No statistically significant differences were observed in OS (p = 0.882) and PFS (p = 0.312) between the groups. Conclusion: No statistically significant differences were observed when comparing groups of patients who received chemotherapy with and without bevacizumab in this cohort of patients with advanced ovarian cancer.